Opportunity Information: Apply for RFA CA 24 025
The National Cancer Institute (NCI), through the National Institutes of Health (NIH), is soliciting applications for a cooperative agreement to run the Data Management, Auditing, and Statistical Center (DMASC) for the Cancer Prevention Clinical Trials Network (CP-CTNet). This opportunity is designed to strengthen and maintain the core infrastructure needed to carry out early-phase cancer prevention clinical trials, specifically phase 0 through phase 2 studies. CP-CTNet is the Division of Cancer Prevention (DCP) main platform for early clinical development of preventive interventions, meaning it focuses on generating the kind of early human evidence that can justify larger, later-stage prevention trials or other downstream development steps.
The clinical trials supported by this network are aimed at testing cancer prevention interventions across multiple organ sites, with an emphasis on understanding biologic effects in people and identifying clinically meaningful correlates (for example, biomarkers, intermediate endpoints, or other measurable signals that show whether an intervention is affecting cancer-related pathways). The larger purpose is not simply to run trials for their own sake, but to produce high-quality evidence that helps decide which preventive strategies are promising enough to advance further. The network is also expected to support collaboration across studies and across participating sites, so that methods, data, and lessons learned can be harmonized and used efficiently.
This particular Notice of Funding Opportunity (NOFO) focuses on the DMASC, which functions as the operational backbone for the network rather than as a trial site. The DMASC is expected to provide centralized database and data management support for multiple trials, ensure that trial data are collected and handled in a consistent and reliable way, and implement auditing functions that protect data integrity and participant safety. In practice, this typically includes building and maintaining clinical trial databases, establishing data standards and quality control procedures, overseeing data submissions and cleaning, supporting regulatory-compliant data handling, and conducting or coordinating audits to verify that sites follow protocols and that data match source documentation when required. On top of that, the DMASC provides statistical leadership and support, which commonly covers study design input, randomization and sample size planning where relevant, statistical analysis plans, interim and final analyses, and consistent reporting that meets NIH/NCI expectations. The NOFO also describes coordinating functions for the network, reflecting the need for a central hub that can keep multi-site, multi-trial activities aligned on timelines, deliverables, and shared procedures.
The award uses the UG1 cooperative agreement mechanism and is marked as a clinical trial required opportunity. A cooperative agreement is different from a standard grant because NIH/NCI expects substantial programmatic involvement during the project, meaning the awardee works closely with NCI staff on planning, oversight, and execution. The funding opportunity is identified as RFA-CA-24-025, categorized as discretionary, and falls under activity areas of education and health. The CFDA numbers listed are 93.393 and 93.399, which align with NCI assistance programs.
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations (other than small businesses); and small businesses. The NOFO also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions. At the same time, it clearly limits foreign participation: non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components are allowed as defined by the NIH Grants Policy Statement, which typically means a U.S. applicant can include certain well-justified foreign elements in the project while keeping the applicant organization and primary infrastructure domestic.
Key timing information included in the source data lists an original closing date of 2024-10-31, and a creation date of 2024-08-12. The award ceiling and expected number of awards are not specified in the provided extract, so applicants would need to consult the full NOFO for budget expectations, project period details, and the anticipated scale of the DMASC effort. Overall, this opportunity is best understood as a call for a capable central center to run the data, quality, auditing, statistical, and coordinating operations that allow CP-CTNet to execute multiple early-phase cancer prevention trials efficiently, credibly, and in close partnership with NCI.Apply for RFA CA 24 025
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399.
- This funding opportunity was created on 2024-08-12.
- Applicants must submit their applications by 2024-10-31. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
1) What is this funding opportunity?
This is a Notice of Funding Opportunity (NOFO) from the National Cancer Institute (NCI) at the National Institutes of Health (NIH) to support a cooperative agreement for the Data Management, Auditing, and Statistical Center (DMASC) for the Cancer Prevention Clinical Trials Network (CP-CTNet).
2) What is the NOFO number for this opportunity?
The funding opportunity identifier is RFA-CA-24-025.
3) What mechanism is being used for the award?
The award uses the UG1 cooperative agreement mechanism.
4) What does "cooperative agreement" mean in this context?
A cooperative agreement differs from a standard grant because NIH/NCI anticipates substantial programmatic involvement during the project. The awardee is expected to work closely with NCI staff on planning, oversight, and execution.
5) Is a clinical trial required under this opportunity?
Yes. The opportunity is marked as a "clinical trial required" funding opportunity.
6) What program or network will the DMASC support?
The DMASC will support the Cancer Prevention Clinical Trials Network (CP-CTNet), which is the Division of Cancer Prevention (DCP) main platform for early clinical development of preventive interventions.
7) What phases of clinical trials does CP-CTNet focus on?
CP-CTNet focuses on early-phase cancer prevention clinical trials, specifically phase 0 through phase 2 studies.
8) What is the main purpose of CP-CTNet-supported trials?
The trials are designed to generate early human evidence about preventive interventions to help determine whether a strategy is promising enough to justify larger, later-stage prevention trials or other downstream development steps.
9) What kinds of interventions and outcomes are emphasized?
The network supports testing cancer prevention interventions across multiple organ sites, with an emphasis on understanding biologic effects in people and identifying clinically meaningful correlates such as biomarkers, intermediate endpoints, or other measurable signals indicating effects on cancer-related pathways.
10) What is the DMASC, in plain terms?
The DMASC is the operational backbone for CP-CTNet. It is a centralized center intended to run data systems, data quality functions, auditing, and statistical leadership to support multiple clinical trials across the network.
11) Is the DMASC expected to function as a trial site?
No. As described, the DMASC functions as centralized infrastructure for the network rather than serving as a clinical trial site.
12) What data management responsibilities are described for the DMASC?
The DMASC is expected to provide centralized database and data management support for multiple trials and ensure trial data are collected and handled in a consistent and reliable way. Activities typically include building and maintaining clinical trial databases, establishing data standards and quality control procedures, overseeing data submissions and cleaning, and supporting regulatory-compliant data handling.
13) What auditing responsibilities are described for the DMASC?
The DMASC is expected to implement auditing functions intended to protect data integrity and participant safety. This includes conducting or coordinating audits to verify that sites follow protocols and that data match source documentation when required.
14) What statistical responsibilities are described for the DMASC?
The DMASC is expected to provide statistical leadership and support. This commonly includes study design input, randomization and sample size planning where relevant, development of statistical analysis plans, interim and final analyses, and consistent reporting that meets NIH/NCI expectations.
15) What coordinating role is described for the DMASC?
The NOFO describes coordinating functions reflecting the need for a central hub to keep multi-site, multi-trial activities aligned on timelines, deliverables, and shared procedures.
16) Why is centralized infrastructure important for this network?
The opportunity emphasizes strengthening and maintaining core infrastructure so multiple early-phase prevention trials can be executed efficiently and credibly, while supporting collaboration and harmonization of methods, data, and lessons learned across studies and participating sites.
17) What are the CFDA numbers associated with this opportunity?
The CFDA numbers listed are 93.393 and 93.399, which align with NCI assistance programs.
18) How is this opportunity categorized in the provided information?
It is categorized as discretionary and falls under activity areas of education and health.
19) Who is eligible to apply (in general)?
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities, including certain government agencies, higher education institutions, nonprofits, and for-profit organizations.
20) Which government entities are eligible to apply?
Eligible applicants include state governments, county governments, city or township governments, special district governments, and independent school districts.
21) Are institutions of higher education eligible?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
22) Are nonprofits eligible?
Yes. Nonprofits with or without 501(c)(3) status are eligible, excluding institutions of higher education within those nonprofit categories as stated in the provided eligibility list.
23) Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) are eligible, and small businesses are also listed as eligible.
24) Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments are eligible, and tribal organizations that are not federally recognized are also listed as eligible.
25) Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are explicitly highlighted as eligible applicant categories.
26) Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly highlighted as eligible applicant categories.
27) Are certain minority-serving institutions specifically highlighted as eligible?
Yes. The NOFO highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs (Asian American Native American Pacific Islander Serving Institutions), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and other highlighted categories.
28) Are eligible federal agencies allowed to apply?
Yes. Eligible federal agencies are explicitly highlighted among eligible applicant categories.
29) Can non-U.S. (foreign) organizations apply?
No. Non-domestic (non-U.S.) entities are not eligible to apply.
30) Can a U.S. organization apply if part of the work is conducted outside the U.S.?
The provided information states that non-domestic components of U.S. organizations are not eligible to apply. It also states that foreign components are allowed as defined by the NIH Grants Policy Statement, meaning certain well-justified foreign elements may be included under NIH policy while the applicant organization and primary infrastructure remain domestic.
31) What is the application closing date shown in the provided information?
The source data lists an original closing date of 2024-10-31.
32) What is the creation date shown in the provided information?
The source data lists a creation date of 2024-08-12.
33) Is the funding amount (award ceiling) provided in the excerpt?
No. The award ceiling is not specified in the provided extract.
34) Is the expected number of awards provided in the excerpt?
No. The expected number of awards is not specified in the provided extract.
35) Where should applicants look for budget expectations and project period details?
The provided information indicates applicants would need to consult the full NOFO for budget expectations, the project period, and the anticipated scale of the DMASC effort.
Browse more opportunities from the same category: Education, Health
Next opportunity: Tribal Pesticide Program Council (TPPC) Technical Support
Previous opportunity: Critical Facility Energy Resilience (CiFER)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 24 025
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 24 025) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required) Apply for RFA CA 24 028 Funding Number: RFA CA 24 028 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed) Apply for PAR 24 269 Funding Number: PAR 24 269 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed) Apply for RFA DA 26 002 Funding Number: RFA DA 26 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed) Apply for RFA DA 26 001 Funding Number: RFA DA 26 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed) Apply for RFA DA 26 008 Funding Number: RFA DA 26 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed) Apply for RFA DA 26 007 Funding Number: RFA DA 26 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional) Apply for RFA CA 25 011 Funding Number: RFA CA 25 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional) Apply for RFA CA 25 012 Funding Number: RFA CA 25 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 24 274 Funding Number: PAR 24 274 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) Apply for RFA DA 25 063 Funding Number: RFA DA 25 063 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional) Apply for PAR 24 273 Funding Number: PAR 24 273 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NLM Information Resource Grants to Reduce Health Disparities and Promote Health Equity (G08 Clinical Trial Not Allowed) Apply for PAR 24 281 Funding Number: PAR 24 281 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) Apply for PAR 25 043 Funding Number: PAR 25 043 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) Apply for PAR 25 044 Funding Number: PAR 25 044 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) Apply for PAR 24 277 Funding Number: PAR 24 277 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) Apply for PAR 24 291 Funding Number: PAR 24 291 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 073 Funding Number: RFA DA 25 073 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional) Apply for PAR 24 297 Funding Number: PAR 24 297 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional) Apply for PAR 24 298 Funding Number: PAR 24 298 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) Apply for PAR 24 299 Funding Number: PAR 24 299 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 24 025", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.